

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims, in the application:

**LISTING OF CLAIMS:**

Claim 1. (currently amended) ~~At least one~~ An isolated mammalian anti-Dengue virus antibody, comprising at least one variable region comprising the amino acid sequence set forth in SEQ ID NOS: ~~3 or~~ NO: 4.

Claim 2. (original) An antibody according to Claim 1, wherein said antibody binds Dengue virus NS-1 protein.

Claim 3. (original) An anti-Dengue virus antibody according to Claim 1, wherein said antibody binds at least one Dengue virus NS protein.

Claims 4-8. (canceled)

Claim 9. (currently amended) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising an amino acid sequence set forth in SEQ ID NOS: ~~3 or~~ NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 10. (currently amended) A composition according to Claim 9, further comprising at least one composition comprising ~~an~~ a therapeutically or prophylactically effective amount of at least one compound or protein selected from ~~at least one of the group consisting of a~~ detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 11. (withdrawn) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 12. (withdrawn) A method according to Claim 11, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 13. (withdrawn) A method according to Claim 11, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 14. (withdrawn) A method according to Claim 11, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from ~~at least one~~ the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 15. (currently amended) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NOS: 3 ~~or~~ NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting

of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 16. (currently amended) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NOS: ~~3 or~~ NO: 4.

Claim 17. (currently amended) The article of manufacture of Claim 16, wherein said container is a component of a delivery device or system using a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal ~~delivery device or system~~.

Claim 18. (canceled)

Claim 19. (currently amended) ~~At least one anti-Dengue virus antibody~~ An isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NO: 4 produced by a method according to Claim 18 comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

Claim 20. (currently amended) ~~At least one~~ An isolated mammalian anti-Dengue virus antibody, comprising ~~either (i) all of the heavy chain complementarity determining regions~~

~~(CDR) amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acid sequences of SEQ ID NO: 4.~~

Claim 21. (original) A Dengue virus antibody according to Claim 20, wherein said antibody binds a Dengue virus NS protein.

Claim 22. (original) A Dengue virus antibody according to Claim 20, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claims 23-27. (canceled)

Claim 28. (currently amended) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having ~~either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acid sequences of SEQ ID NO: 4;~~ and at least one pharmaceutically acceptable carrier or diluent.

Claim 29. (currently amended) A composition according to Claim 28, further comprising at least one composition comprising ~~an~~ a therapeutically or prophylactically effective amount of at least one compound or protein selected from ~~at least one of the group consisting of~~ a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 30. (withdrawn) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient, animal or population of subjects comprising:  
(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 20, with, or to, said cell, tissue, organ, patient or animal.

Claim 31. (withdrawn) A method according to Claim 30, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 32. (withdrawn) A method according to Claim 30, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 33. (withdrawn) A method according to Claim 30, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising ~~an~~ a therapeutically or prophylactically effective amount of at least one compound or protein selected from ~~at least one of~~ the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 34. (currently amended) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having ~~either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of~~ SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 35. (currently amended) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having ~~either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NO: 4.~~

Claim 36. (currently amended) The article of manufacture of Claim 35, wherein said container is a component of a delivery device or system which uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal delivery device or system.

Claim 37. (canceled)

Claim 38. (currently amended) ~~At least one anti-Dengue virus antibody~~ An isolated mammalian anti-Dengue virus antibody having all of the light chain CDR amino acid sequence of SEQ ID NO: 4 produced by a method according to Claim 37 comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts nucleic acid molecules encoding said antibody.

Claim 39. (currently amended) ~~At least one~~ An isolated mammalian anti-Dengue virus antibody, comprising at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of ~~at least one of~~ SEQ ID NOS: 3 ~~or~~ NO: 4.

Claim 40. (original) A Dengue virus antibody according to Claim 39, wherein said antibody binds a Dengue virus NS protein.

Claim 41. (original) A Dengue virus antibody according to Claim 39, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claims 42-46. (canceled)

Claim 47. (currently amended) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: ~~3 or~~ NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 48. (currently amended) A composition according to Claim 47, further comprising at least one composition comprising ~~an~~ a therapeutically or prophylactically effective amount of at least one compound or protein selected from ~~at least one of the group consisting of~~ a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 49. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 50. (withdrawn) A method according to Claim 49, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 51. (withdrawn) A method according to Claim 49, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 52. (withdrawn) A method according to Claim 49, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from ~~at least one~~ the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 53. (currently amended) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of ~~at least one of SEQ ID NOS: 3 or~~ NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 54. (currently amended) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody, having at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of ~~at least one of SEQ ID NOS: 3 or~~ NO: 4.

Claim 55. (currently amended) The article of manufacture of Claim 54, wherein said container is a component of a delivery device or system that uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic,



intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal ~~delivery device or system~~.

Claim 56. (canceled)

Claim 57. (currently amended) ~~At least one anti-Dengue virus antibody~~ An isolated mammalian anti-Dengue virus antibody having at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4 produced by a method according to Claim 56 comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing a nucleic acid molecule encoding said antibody in recoverable amounts wherein said nucleic acid molecule comprises SEQ ID NO: 1 ~~or~~ 2.

Claim 58. (currently amended) ~~At least one~~ An isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of ~~at least one of~~ SEQ ID NOS: ~~3 or~~ NO: 4.

Claim 59. (original) A Dengue virus antibody according to Claim 58, wherein said antibody binds a Dengue virus NS protein.

Claim 60. (original) A Dengue virus antibody according to Claim 58, wherein said antibody substantially neutralizes at least one activity of at least one Dengue virus protein.

Claims 61-65. (canceled)

Claim 66. (currently amended) A composition comprising at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of ~~at least one of~~ SEQ ID NOS: ~~3 or~~ NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 67. (currently amended) A composition according to Claim 66, further comprising at least one composition comprising ~~an~~ a therapeutically or prophylactically

effective amount of at least one compound or protein selected from ~~at least one of the group~~ consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 68. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as the antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 69. (withdrawn) A method according to Claim 68, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 70. (withdrawn) A method according to Claim 68, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 71. (withdrawn) A method according to Claim 68, further comprising administering, prior, concurrently or after said step (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from ~~at least one of the group consisting of~~ a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an

anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 72. (currently amended)      A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of ~~at least one of~~ SEQ ID NOS: 3 ~~or~~ NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 73. (currently amended)      An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one ~~heavy chain or~~ light chain CDR having the amino acid sequence of ~~at least one of~~ SEQ ID NOS: 3 ~~or~~ NO: 4.

Claim 74. (currently amended)      The article of manufacture of Claim 73, wherein said container is a component of a delivery device or system which uses a mode of delivery selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,

intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or and~~ transdermal delivery device or system.

Claim 75. (canceled)

Claim 76. (currently amended) ~~At least one anti-Dengue virus antibody~~ An isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4 produced by a method according to Claim 75 comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

Claim 77. (currently amended) ~~At least one~~ An isolated population of monoclonal mammalian anti-Dengue virus antibody antibodies, comprising at least one human CDR, wherein said ~~antibody~~ antibodies specifically ~~binds~~ bind at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of a Dengue virus NS protein.

Claim 78. (currently amended) ~~A~~ The Dengue virus ~~antibody~~ antibodies according to Claim 77, wherein said ~~antibody binds~~ antibodies bind a Dengue virus NS1 protein.

Claim 79. (currently amended) ~~A~~ The Dengue virus ~~antibody~~ antibodies according to Claim 77, wherein said ~~antibody~~ antibodies substantially ~~neutralizes~~ neutralize at least one activity of at least one Dengue virus NS protein.

Claims 80-84. (canceled)

Claim 85. (currently amended) A composition comprising ~~at least one~~ an isolated population of monoclonal mammalian anti-Dengue virus ~~antibody~~ antibodies having at least one human CDR, wherein said ~~antibody~~ antibodies specifically ~~binds~~ bind at least one epitope comprising two or more amino acids of Dengue virus NS1 protein, and at least one pharmaceutically acceptable carrier or diluent.

Claim 86. (currently amended) A composition according to Claim 85, further comprising at least one composition comprising ~~an~~ a therapeutically or prophylactically effective amount of at least one compound or protein selected from at least one of the group

consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 87. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 77, with, or to, said cell, tissue, organ, patient or animal.

Claim 88. (withdrawn) A method according to Claim 87, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 89. (withdrawn) A method according to Claim 87, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.

Claim 90. (withdrawn) A method according to Claim 87, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from ~~at least one of~~ the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement

drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, ~~or~~ and a cytokine antagonist.

Claim 91. (currently amended) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody or a nucleic acid molecule encoding said antibody, having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of a Dengue virus NS protein, wherein said device is suitable to contacting or administering said ~~at least one~~ anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelal, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 92. (original) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or a nucleic acid molecule encoding said antibody, having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein.

Claim 93. (currently amended) The article of manufacture of Claim 92, wherein said container is a component of a delivery device or system which uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelal, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or and transdermal delivery device or system.~~

Claim 94. (canceled)

Claim 95. (currently amended)      ~~At least one~~ A population of monoclonal mammalian anti-Dengue virus antibody ~~antibodies~~ having at least one human CDR wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein, produced by a method ~~according to Claim 94~~ comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibodies.